"Aibo Biotechnology's plate is too big. My funds are limited and it is impossible to invest them all at once."

Aibo Biotech is the leading domestic company in the field of mRNA vaccines. Their Series B financing of up to 600 million RMB has just been completed, and they will soon make a Series C investment amounting to more than 700 million RMB.

The field of biomedicine is a very, very money-burning field, especially for companies that produce innovative drugs. It is not uncommon for billions of dollars to be wasted.

The stocks strategically placed by Cheng Gang will be lifted in two years at the earliest. He has to spend up to 20 million RMB in cash on hand. Even if he borrows the original shares of Kechuang Biotechnology, he will only borrow about 100 million RMB.

120 million invested in innovative drugs, let alone wasted, are not even qualified to take a look.

"Furthermore, the concept that Abbot Biotech can compete with foreign pharmaceutical giants in mRNA is too small." Cheng Gang reminded.

Young considers himself to be the strategist, especially after investing in Science and Technology Biotechnology, he has a higher voice within IDG.

"Aibo does not need to compete with Pfizer and Modena, it only needs to compete with Microbiology. Besides, both IDG companies have also invested."

Si Microbiology is another domestic biopharmaceutical company that produces mRNA.

Cheng Gang patted his forehead: "Kechuang Biotech is about to go on the market. I've been having a hard time thinking right now."

Young's subtext is that the mRNA vaccines of foreign pharmaceutical giants cannot enter the Chinese market at all. As long as Aibo and Siwei can capture most of the Chinese market, they can already make a lot of money.

"You are too sophisticated. You put eggs in both baskets and there will be no losses at all." Cheng Gang said with emotion: "The project management of foreign investment banks needs to be more shrewd in their calculations."

Regardless of whether the research and development of Si microorganisms or the research and development of Aibo Biotech is successful, the return obtained by IDG is more than 10 times, which is equivalent to investing 2 and getting 10.

Back then, when venture capital invested in Internet companies, they invested in all leading companies. As long as one of them went public, its return rate would be at least 50%.

As long as there is no overturning incident and a third-party company that you did not invest in catches up, this investment will be a sure profit.

No matter which investment method you choose, black swans will appear, and even asset management products may experience thunderstorms.

Therefore, when some angel investors communicate privately, they claim that angel investment is essentially low-risk and high-yield. Of course, experts can say this and laymen can just listen.

This is wild talk during an upturn in the economic cycle. Let’s see if they dare to say it when the economic cycle is down.

"How about it? Do you want to invest? I can give you part of IDG's shares."

This is a more advanced xinghui method, euphemistically called benefit exchange.

When someone tells you that a stock will definitely rise next week, and even tells you how many points it will rise from day to day, and the maximum number of shares you can buy, will you buy it?

Cheng Gang thought for a moment and then nodded and said, "I'll think about it and give you an answer later."

Young: "Decide as soon as possible. The project of Aibo Biology is very urgent, and their need for funds is very urgent."

"In fact, you don't need to set up an investment company. Isn't the big ship of Science and Technology Biotechnology good?"

"You have completely achieved wealth freedom through this strategic placement, so why bother?"

Sharing the investment share to Cheng Gang was just a casual move for Young. His investment was more skillful and subtle than what Li Miaomiao encountered before.

And there was no violation at all, and it didn’t even violate human ethics. I was just helping my friends to make connections, and the investment behavior was completely legitimate.

Cheng Gang has been around for so many years and is naturally a good person. He knows that Young is provoking him:

"We also met when we were at Amerikan. You became wealthy and free many years before I did. Why can't you stop playing around with it all these years?"

"We are the same on this point. Anyone who has started a business cannot stop. Their excitement threshold has been raised and daily life cannot stimulate them."

"If you don't do something that interests you, you will be no different from the dead bones in the grave. You won't feel anything anyway."

Cheng Gang and Young were both members of the European and American Alumni Association, and Cheng Gang was also in the venture capital circle, so the two had occasionally communicated with each other before.

Cheng Gang was very emotional after finishing the meeting with Young. Although they had known each other before, he was at a lower level than Young and the communication between the two parties was very limited.

Cheng Gang was previously one of the investment directors of Shunwei Capital. To put it bluntly, he was a senior migrant worker. Young was a partner of IDG Capital and was one of the shareholders. Small shareholders are also shareholders.

"If it were me before, I would not know which companies would participate in the C-round investment of Aibo Biotechnology until the C-round investment agreement is finalized."

"Not to mention getting investment opportunities."

"Shunwei Capital has also invested a lot in the biomedical field in the past two years due to its participation in the A-round investment of Kechuang Biotech. I don't know why they did not invest in Aibo Biotech this time."

"Although this matter is neither illegal nor against company regulations, I still report it to Director Zheng."

"If I am disliked by Director Zheng because of this incident and it subsequently affects my position in Science and Technology Biotechnology, it will be a big loss."

Cheng Gang is very self-aware. He knows that he can invest in the field of biomedicine. Others are willing to take him not because he has a PhD in biomedicine, but because he is the general manager of Kechuang Biotech.

If he loses this position, he can only invest in a small start-up company, or become a partner in a venture capital company, and rely on the resume of Science and Technology Biotechnology to improve himself to a higher level than before.

But compared to what we do at Kechuang Biotechnology, it's still far behind.

"Recently, a new biomedical park is being built in Susu. It is said that they will vigorously develop the biomedical industry, and Aibo Biotechnology is said to be their strong support project."

"If Aibo Biotech can really become the next scientific and technological innovation, then it can be said that Susu's biomedical industry cluster is expected to be established."

A cluster cannot rely on one enterprise. It needs successors and other related enterprises to support the entire industrial cluster.

For example, Ali has not only Ali in Hangzhou, but also a bunch of good Internet companies such as Ant Financial, Zhuchang, Mogujie, and Tongdun.

"Aibo Biotechnology is located in Suzhou. After Kechuang Biotech is launched, we can go and do some research to see their technical strength."

"We can participate in one investment as Science and Technology Biotechnology, and I will participate in another investment in my own name."

Cheng Gang was sitting in the car going home, thinking about all kinds of things in his mind.

"If you want to invest, you can invest. Whether it is investing in Aibo Biotech or Siwei, I have no objection."

"If you want to set up a venture capital company, I have no objection, but you must distinguish between public and private matters, and you cannot put your personal interests above the interests of the company."
Chapter completed!